99mTc-Radiolabelled Peptides for Tumour Imaging: Present and Future

Title: 99mTc-Radiolabelled Peptides for Tumour Imaging: Present and Future

Volume: 17 Issue: 24

Author(s): C. Bolzati, F. Refosco, A. Marchiani and P. Ruzza

Affiliation:

Keywords: Peptide receptors, radiolabelled peptides, technetium, tumour imaging

Abstract: Receptor-binding peptides have attracted an enormous interest in targeting molecules for the development of tumour specific radiopharmaceutical compounds. The overexpression of many receptors on human tumour makes such peptide-ligands attractive agents for diagnostic imaging and therapy of cancers. The use of solid-phase peptide synthesis and the availability of a wide range of bifunctional chelating agents for the radiolabelling of bioactive peptides with radionuclides have produced a wide variety of useful radiopharmaceutical molecules. For diagnostic purposes, techenetium- 99m is the ideal radionuclide thanks to its nuclear properties and the availability of a low cost portable generator system.

Cite this article as:

Bolzati C., Refosco F., Marchiani A. and Ruzza P., 99mTc-Radiolabelled Peptides for Tumour Imaging: Present and Future, Current Medicinal Chemistry 2010; 17 (24) . https://dx.doi.org/10.2174/092986710791859388